Pharmacological and Clinical Evaluation of Telotristat Ethyl: A Peripheral Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
- VernacularTitle:治疗类癌综合征的外周色氨酸羟化酶抑制药特罗司他乙酯的药理与临床评价
- Author:
Lufeng XIA
1
;
Yongchuan HU
;
Lei LIU
Author Information
1. 北京医院药学部 国家老年医学中心 北京100730
- Keywords:
Telotristat ethyl;
Tryptophan hydroxylase;
Carcinoid syndrome;
Diarrhea
- From:
China Pharmacist
2018;21(5):901-904
- CountryChina
- Language:Chinese
-
Abstract:
Telotristat ethyl is a peripheral tryptophan hydroxylase (TPH) inhibitor for the treatment of carcinoid syndrome. Telotristat ethyl inhibits TPH,thereby reducing the production of serotoin(5-HT) and the daily bowel movement. Pharmacology, pharmacokinetics,clinical studies and safety of telotristat ethyl were reviewed in the paper. Telotristat ethyl has become a novel treatment option for carcinoid syndrome patients. Telotristat ethyl is well tolerated with low incidence of side effects.
